Composition comprising meloside for alleviating hair loss and improving hair growth

Abstract

The present invention relates to a composition comprising meloside for alleviating hair loss and improving hair growth and, more specifically, to a composition for alleviating hair loss and improving hair growth, the composition comprising, as an active ingredient, meloside that allows the growth / proliferation of dermal papilla cells and inhibits the expression / activity of the androgen receptor.

Description

Composition for alleviating hair loss and improving hair growth containing meloside

[0001] The present invention relates to a composition for alleviating hair loss and improving hair growth, including meloside, and more specifically, to a composition for alleviating hair loss and improving hair growth, including meloside as an active ingredient, which promotes the growth / proliferation of hair papilla cells and suppresses the expression / activity of androgen receptors.

[0002] The hair growth cycle consists of three phases: anagen (growth), catagen (regression), and telogen (resting) phases, and is maintained through a cycle of hair growth and hair loss. Specifically, the hair growth phase is divided into the anagen phase, during which hair growth ceases and the hair bulb shrinks (catagen), and the telogen phase, during which the hair papilla begins to function or hair growth occurs, leading to hair loss.

[0003] The growth phase of hair lasts about 3 to 5 years for men and 4 to 6 years for women, the regression phase lasts about 60 to 90 days, and the resting phase lasts about 90 to 120 days before natural hair loss occurs.

[0004] Hair loss can be categorized into male pattern baldness, female pattern baldness, telogen effluvium, alopecia areata, and stress-induced alopecia. It can be caused by a variety of factors, including genetic, environmental, psychological, and hormonal changes. Hair loss occurs simultaneously, with multiple hairs failing to grow and falling out, and the proportion of hair that has stopped growing increases.

[0005] In particular, male pattern baldness is known to be caused by hormonal factors. Testosterone, the male hormone, is converted to dihydrotestosterone (DHT) by 5-alpha reductase, which acts directly on hair follicles. DHT induces hair follicles into atrophy, leading to hair loss. Excessive DHT increases hair thinning and hair loss, and accelerates hair thinning and hair loss at the crown, exacerbating hair loss.

[0006] Furthermore, DHT, produced by testosterone, acts directly on the dermal papilla cells of the hair follicle, increasing the expression of androgen receptors. The androgen receptor is a nuclear translocation factor. When it binds to DHT and translocates to the nucleus, it increases the expression of hair loss-inducing factors such as dickkopf1, TNF-α, TGF-α, and IL-1, and induces the inhibition of Wnt signaling factors, resulting in hair loss. Therefore, methods that regulate the expression of androgen receptors in dermal papilla cells are used to treat alopecia caused by these causes.

[0007] Under these technical backgrounds, the inventors of the present invention have made efforts to develop a composition for alleviating hair loss and improving hair growth, particularly a composition for preventing male pattern baldness or improving hair growth, and as a result, have discovered that a composition containing meloside as an active ingredient has the effect of promoting the growth / proliferation of hair papilla cells and inhibiting the expression / activity of androgen receptors, thereby completing the present invention.

[0008] [Prior Art Literature]

[0009] Republic of Korea Patent Publication No. 10-2011-0064989 (June 15, 2011)

[0010] The main purpose of the present invention is to provide a composition for alleviating hair loss and improving hair growth, which comprises meloside, an isomer thereof, a hydrate thereof, a solvate thereof or a salt thereof as an active ingredient.

[0011] Another object of the present invention is to provide a pharmaceutical product, a health functional food product, and a cosmetic product manufactured from the composition.

[0012] In order to achieve the above purpose, the present invention provides a composition for alleviating hair loss and improving hair growth, which comprises, as an active ingredient, meloside represented by the following chemical formula 1, preferably meloside A represented by the following chemical formula 2 and / or meloside L represented by the following chemical formula 3, an isomer thereof, a hydrate thereof, a solvate thereof or a salt thereof.

[0013] [Chemical Formula 1]

[0014]

[0015] [Chemical Formula 2]

[0016]

[0017] [Chemical Formula 3]

[0018]

[0019] The present invention provides a composition for preventing male pattern baldness or improving hair growth, comprising as an active ingredient meloside represented by chemical formula 1, preferably meloside A represented by chemical formula 2 and / or meloside L represented by chemical formula 3, an isomer thereof, a hydrate thereof, a solvate thereof or a salt thereof.

[0020] In addition, the present invention provides a composition for inhibiting growth / proliferation of breast papilla cells and expression / activity of androgen receptors, comprising as an active ingredient meloside represented by chemical formula 1, preferably meloside A represented by chemical formula 2 and / or meloside L represented by chemical formula 3, an isomer thereof, a hydrate thereof, a solvate thereof or a salt thereof.

[0021] In addition, the present invention provides a drug, health functional food and cosmetic manufactured from a composition containing, as an active ingredient, meloside represented by chemical formula 1, preferably meloside A represented by chemical formula 2 and / or meloside L represented by chemical formula 3, an isomer thereof, a hydrate thereof, a solvate thereof or a salt thereof.

[0022] In addition, the present invention provides the use of meloside represented by chemical formula 1, preferably meloside A represented by chemical formula 2 and / or meloside L represented by chemical formula 3, an isomer thereof, a hydrate thereof, a solvate thereof or a salt thereof as an effective ingredient in the manufacture of a composition for alleviating hair loss and improving hair growth.

[0023] The composition for alleviating hair loss and improving hair growth containing meloside according to the present invention has excellent effects of inhibiting the growth / proliferation of hair papilla cells and the expression / activity of androgen receptors, and can be used in the manufacture of cosmetics, drugs, etc. for preventing hair loss or improving hair growth.

[0024] Figure 1 is a graph showing the growth / proliferation effect of meloside A / meloside L on mammary gland cells according to one embodiment of the present invention.

[0025] Figure 2 is a graph showing the effect of meloside A / meloside L on the growth / proliferation of outer root cells according to one embodiment of the present invention.

[0026] Figure 3 shows the Western blot results showing the male pattern baldness improvement effect of meloside A / meloside L according to one embodiment of the present invention.

[0027] Figure 4 is a graph showing the quantitative results of the Western blot of Figure 3.

[0028] Figure 5 shows the androgen receptor nuclear translocation inhibition effect of meloside A / meloside L according to one embodiment of the present invention, as observed under a fluorescence microscope.

[0029] Figure 6 is a graph that quantifies the fluorescence microscopy observation results of Figure 5.

[0030] Figure 7 is a graph showing the DKK1 expression inhibition effect of meloside A / meloside L according to one embodiment of the present invention.

[0031] Figure 8 is a graph showing the VEGF increasing effect of meloside A / meloside L according to one embodiment of the present invention.

[0032] Figure 9 is a graph showing the cell death inhibition effect of meloside A / meloside L by dihydrotestosterone according to one embodiment of the present invention.

[0033] Figure 10 is a graph showing the cell death inhibition effect of meloside A / meloside L on DKK1 according to one embodiment of the present invention.

[0034] Figure 11 is a graph showing the hair loss inflammation alleviation effect of Meloside A / Meloside L according to one embodiment of the present invention.

[0035] Figure 12 shows the oxygen radical inhibition effect of meloside A / meloside L according to one embodiment of the present invention as observed under a fluorescence microscope.

[0036] Figure 13 is a graph showing the quantified results of the fluorescence microscopy observation of Figure 12.

[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Generally, the nomenclature used herein is well known and commonly used in the art.

[0038] Hereinafter, the present invention will be described in more detail.

[0039] The term "about" used in this specification to express length, area, volume, time (duration), concentration, content, temperature, number, percentage (%), multiple, etc. means that there is a tolerance of up to 10% in the corresponding value or range of values.

[0040] In one aspect, the present invention relates to a composition comprising, as an active ingredient, meloside represented by the following chemical formula 1, preferably meloside A represented by the following chemical formula 2 and / or meloside L represented by the following chemical formula 3, more preferably meloside A, an isomer thereof, a hydrate thereof, a solvate thereof or a salt thereof, and specifically to a composition for alleviating hair loss and improving hair growth.

[0041] [Chemical Formula 1]

[0042]

[0043] [Chemical Formula 2]

[0044]

[0045] [Chemical Formula 3]

[0046]

[0047] In addition, the present invention provides the use of meloside represented by the above chemical formula 1, preferably meloside A represented by the above chemical formula 2 and / or meloside L represented by the above chemical formula 3, an isomer thereof, a hydrate thereof, a solvate thereof or a salt thereof as an effective ingredient in the manufacture of a composition for alleviating hair loss and improving hair growth.

[0048] The above Meloside A (isovitexin 2''-O-glucoside) is represented by chemical formula 2, and Meloside L (isoorientin 2''-O-glucoside) is represented by chemical formula 3 (see https: / pubchem.ncbi.nlm.nih.gov / compound / Meloside-A; https: / pubchem.ncbi.nlm.nih.gov / compound / Meloside-L).

[0049] In this specification, isomers are meant to include not only stereoisomers including optical isomers, but also conformation isomers (i.e., isomers that differ only in the angles of one or more chemical bonds), position isomers (particularly, tautomers) or geometric isomers (e.g., cis-trans isomers).

[0050] Also, in this specification, “hydrate” means a compound to which water is bound, and includes an inclusion compound in which there is no chemical bonding between water and the compound.

[0051] Also, in this specification, “solvate” means a compound formed between molecules or ions of a solute and molecules or ions of a solvent.

[0052] In the present invention, the hair may be any hair or fur on the body of a mammal including a human, such as scalp hair, eyebrows, eyelashes, a mustache, a beard, chest hair, back hair, arm hair, leg hair, genital hair, nose hair or ear hair, but is not limited thereto, and is preferably scalp hair.

[0053] In the present invention, the composition may be characterized by increasing the growth / proliferation of breast papilla cells and decreasing the expression of androgen receptors.

[0054] In the present invention, the composition may be characterized by preventing the death of hair follicle cells, alleviating scalp inflammation, and reducing the production of active oxygen, a factor causing hair loss.

[0055] In the present invention, the content of the effective ingredient included in the composition may be characterized as being 10 to 1000 ppm, preferably 10 to 100 ppm, and most preferably 20 to 30 ppm, based on the total weight of the composition. If the content of at least one of the melosides, preferably meloside A and meloside L, is less than 10 ppm based on the total weight of the composition, the hair loss alleviation and hair growth improvement effect is minimal, and if it exceeds 100 ppm, the increase in the effect is not significant compared to the increase in the content, and the stability of the formulation and the feeling of use may be reduced.

[0056] The above composition can be commercialized in various formulations (cosmetics, health functional foods, pharmaceuticals, etc.), and can be appropriately formulated considering the functionality, cost, and other conditions of the product to be implemented.

[0057] The above composition is a cosmetic composition, and may be, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, shampoo, conditioner, and spray, and the formulation is not particularly limited and may be appropriately selected depending on the purpose.

[0058] The above composition is a health functional food composition, for example, a health supplement, and may be in the form of a powder, granule, tablet, capsule, beverage, etc., but is not limited thereto.

[0059] The above active ingredient may be a prodrug of meloside. A prodrug is a drug that has been chemically changed to control its physical and chemical properties. It refers to a drug that does not exhibit physiological activity itself, but is converted into the original drug through chemical or enzymatic action in the body after administration and can exhibit a medicinal effect.

[0060] The above composition may be a pharmaceutical composition, for example, in the form of a tablet, ointment, lotion, gel, cream, spray, suspension, emulsion, patch, etc., but is not limited thereto.

[0061] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.

[0062]

[0063] [reagent]

[0064] Meloside A was obtained from ChemFace, and Meloside L was isolated / purified according to the method described below and used in the experiments. The reagents used in the cell culture and test examples 1 and 2 described below are products of Sigma-Aldrich, unless the manufacturer / source of acquisition is indicated.

[0065]

[0066] [Isolation and purification of meloside L]

[0067] Meloside L was isolated / purified from the flower of the common daisy and applied to the experiment. The aerial parts of the common daisy flower were reflux-extracted with 70% ethanol, and the soft extract concentrated using a rotary vacuum evaporator was solvent-fractionated with n-hexane, ethyl acetate, and n-butanol. The ethyl acetate fraction was applied to column chromatography to isolate a single compound, and silica gel and ODS (octadecylsilane) were used as the stationary phase. The isolated / purified material was analyzed by NMR (1 H, 13 The structure was confirmed through C NMR analysis.

[0068]

[0069] [Cell culture]

[0070] Human hair dermal papilla cells (HDPCs) used in the test examples described below were cultured in an incubator at 37°C, 5% CO2, and humid conditions using DMEM (Dulbecco's Modified Eagle Medium, WELGENE) supplemented with 10% FBS (Fetal Bovine Serum, WELGENE) and 1% antibiotics (Penicillin-Streptomycin, WELGENE) as a culture medium.

[0071] Human Hair Outer Root Sheath Cells (ORS) used in the experimental examples described below were cultured in a culture plate coated with Poly-L-Lysine using MSCM (Mesenchymal Stem Cell Medium, ScienCell) supplemented with 5% FBS (Fetal Bovine Serum, ScienCell), 1% MSCGS (Mesenchymal stem cell growth supplement, ScienCell) and antibiotics (Penicillin-Streptomycin, ScienCell) as a culture medium, in an incubator at 37°C, 5% CO2 and humid conditions.

[0072]

[0073] [Statistical processing]

[0074] Statistical analysis was performed using the t-test method to test the significance between the two groups, and a significant difference was considered when *P<0.05, **P<0.01, ***P<0.001 compared to the negative control group.

[0075]

[0076] [Experimental Example 1] Confirmation of the cytotoxicity of meloside on mammary papilla cells and outer root sheath cells.

[0077] We investigated whether meloside exhibited cytotoxicity against hair papilla cells and root sheath cells and affected their growth / proliferation.

[0078] Specifically, HDPCs, which are hair papilla cells, or ORS, which are outer root sheath cells, were treated with meloside A or meloside L at concentrations of 10, 30, 50, and 100 ppm, respectively, for 1 day. Then, the CCK-8 (Cell counting kit-8, Dojindo, EU) reagent was added to the treated HDPCs according to the manufacturer's protocol, and the absorbance was measured at a wavelength of 450 nm in a microplate reader (BioTeK, USA). The growth / proliferation of hair papilla cells due to meloside treatment was confirmed by comparison with the negative control group (DMEM treatment instead of meloside A or L). The treatment results for HDPCs are shown in Fig. 1, and the treatment results for ORS are shown in Fig. 2.

[0079] As shown in Figures 1 and 2, HDPC and ORS treated with meloside A or L showed cell growth / proliferation levels equivalent to those of the negative control group, confirming that there were no cytotoxic effects such as reducing the growth / proliferation of hair papilla cells and outer root sheath cells.

[0080]

[0081] [Experimental Example 2] Confirmation of the improvement effect of male pattern baldness following meloside treatment.

[0082] In this experimental example, the effect of meloside (specifically, meloside A and L) on the expression of androgen receptors was evaluated to confirm whether it has the effect of improving male pattern baldness.

[0083] Specifically, (i) a negative control group in which neither dihydrotestosterone (DHT) nor meloside A and L was treated to HDPCs, which are hair papilla cells; (ii) an untreated group in which HDPCs were treated with 1 μM DHT and neither meloside A nor L was treated; (iii) a positive control group in which HDPCs were treated with 1 μM DHT and 100 μM minoxidil was treated instead of meloside A and L; and (iv) a treatment group in which HDPCs were treated with 1 μM DHT to activate the androgen receptor and then treated with meloside A or L at a concentration of 30 or 100 ppm for 1 day, respectively; and then the HDPCs from (i) to (iv) were dissolved and the expression level of the androgen receptor (AR) was confirmed to increase or decrease using the Western blotting technique. Here, the expression level of actin was corrected as a standard for the analysis of the relative expression pattern for each sample. The expression pattern confirmed by Western blot is shown in Figure 3, and the result of correcting the relative AR expression level based on the expression level of actin is shown in Figure 4.

[0084] As shown in Figures 3 and 4, the decrease in the expression level of androgen receptor (AR) in HDPC treated with meloside A or L decreased the formation of a complex of AR and DHT in a concentration-dependent manner, confirming the effect of improving hair loss (preventing hair loss, etc.) due to the decrease in AR activity.

[0085] In addition, it was confirmed that meloside A was more effective than meloside L in reducing the expression of androgen receptor (AR).

[0086]

[0087] [Experimental Example 3] Confirmation of the effect of meloside treatment on the inhibition of androgen receptor nuclear translocation.

[0088] The androgen receptor is a transcription factor, a protein that binds to specific sites on DNA and regulates transcription. Specific transcription factors mediate the activation or repression of specific genes.

[0089] Nuclear translocation of the androgen receptor is known to suppress genes of the Wnt signaling system that suppresses hair loss and increases the expression of DKK1, a hair loss-inducing protein (Cell Death & Disease volume 11, Article number: 407 (2020)).

[0090] To confirm whether androgen receptor is involved in hair loss-related gene transcription, a recombinant plasmid, EGFP-AR (Addgene), was used, and the degree of nuclear translocation of androgen receptor in hair papilla cells was measured using an intracellular injection method.

[0091] The untreated group was treated with DHT alone, and the negative control group was treated with neither DHT nor the sample. The experimental group was treated with DHT and 100 ppm of meloside A or L together, and after 24 hours, the Ex 485 nm, Em 535 nm were measured using a fluorescence microscope. The results of the fluorescence microscope observation are shown in Fig. 5, and the number of cells with androgen receptor translocation in the treated group compared to the untreated group is shown in Fig. 6.

[0092] As shown in Figures 5 and 6, it was confirmed that androgen receptor translocation induced by DHT was inhibited by meloside A and L. The effect of inhibiting androgen receptor translocation was confirmed to have a hair loss alleviation effect by reducing the expression level of hair loss-inducing genes. It was confirmed that the efficacy of meloside A was superior to that of meloside L treatment.

[0093]

[0094] [Experimental Example 4] Confirmation of the effect of meloside treatment on DKK1 expression suppression.

[0095] We confirmed whether meloside has the effect of regulating the expression level of DKK1, a downstream step of the androgen receptor.

[0096] After increasing the expression level of DKK1 by treating HDPC with DHT, the cells were treated with meloside A or L at a concentration of 30 or 100 ppm for 1 day, respectively, and the cell supernatant was obtained. For comparison, HDPC treated with DHT (Dihydrotestosterone) but not meloside A or L were used as the untreated group, and HDPC treated with 100 μM minoxidil were used as the positive control group.

[0097] The supernatant of the obtained cells was used to confirm whether the expression level of DKK1 increased or decreased using enzyme-linked immunosorbent assay, and the results are shown in Figure 7.

[0098] As shown in Fig. 7, the concentration-dependent decrease in DKK1 expression in HDPC treated with meloside A confirmed the hair loss alleviation effect by reducing the inhibition of the Wnt signaling system, but meloside L had no effect.

[0099]

[0100] [Experimental Example 5] Confirmation of VEGF effects following meloside treatment

[0101] To confirm the hair growth promoting effect of meloside A and L, we evaluated the expression level of VEGF (Vascular Endothelial Growth Factor), a growth factor known to promote hair growth by participating in the expansion and formation of blood vessels.

[0102] HDPCs were treated with meloside A or L at concentrations of 30 or 100 ppm, respectively, for 1 day, and cell supernatants were obtained. For comparison, HDPCs not treated with meloside A or L were used as a negative control group, and HDPCs treated with 100 μM minoxidil were used as a positive control group.

[0103] The supernatant of the obtained cells was used to determine whether there was an increase or decrease in the expression level of VEGF using enzyme-linked immunosorbent assay, and the results are shown in Figure 8.

[0104] As shown in Fig. 8, the increase in the expression level of VEGF in HDPC treated with meloside A and L helped improve blood circulation, confirming the hair loss alleviation effect. It was confirmed that the blood circulation improvement effect of meloside A was superior to that of meloside L.

[0105]

[0106] [Experimental Example 6] Confirmation of the inhibitory effect of dihydrotestosterone (DHT) on cell death by meloside treatment.

[0107] We confirmed the protective effect of meloside A and L against DHT, which induces apoptosis of human hair papilla cells (HDPCs).

[0108] Specifically, HDPCs, which are hair papilla cells, were treated with 30 or 100 ppm of meloside A or L for 1 day, respectively, and then cell death was induced with DHT (Dihydrotestosterone). For comparison, HDPCs that were not treated with meloside A or L and not treated with DHT were used as a negative control group, HDPCs that were not treated with meloside A or L and treated with DHT were used as an untreated group, and HDPCs that were treated with 100 μM minoxidil or 5 mM N-acetyl cysteine ​​(NAC) and then treated with DHT were used as a positive control group.

[0109] The reagent of CCK-8 (Cell counting kit-8, Dojindo, EU) was added to HDPC according to the manufacturer's protocol, and the absorbance was measured at a wavelength of 450 nm in a microplate reader (BioTeK, USA). The cell viability of dermal papilla cells treated with meloside was compared with that of the negative control group (DMEM treatment instead of meloside A or L). The results are shown in Fig. 9.

[0110] As shown in Fig. 9, a cytoprotective effect against DHT was confirmed in HDPC treated with meloside A. On the other hand, a cytoprotective effect against DHT was confirmed to be absent in HDPC treated with meloside L.

[0111]

[0112] [Experimental Example 7] Confirmation of the Inhibitory Effect of DKK1 on Cell Death by Meloside Treatment

[0113] We confirmed the protective effect of meloside A and L on DKK1, which induces apoptosis of human hair papilla cells (HDPCs).

[0114] Specifically, HDPCs, which are hair papilla cells, were treated with 30 or 100 ppm of meloside A or L for 1 day, respectively, and then apoptosis was induced with DKK1 (dickkopf WNT signaling pathway inhibitor 1). For comparison, HDPCs that were not treated with meloside A or L and not treated with DHT were used as a negative control group, HDPCs that were not treated with meloside A or L and treated with DHT were used as an untreated group, and HDPCs that were treated with 100 μM minoxidil or 5 mM NAC and then treated with DHT were used as a positive control group.

[0115] The reagent of CCK-8 (Cell counting kit-8, Dojindo, EU) was added to HDPC according to the manufacturer's protocol, and the absorbance was measured at a wavelength of 450 nm in a microplate reader (BioTeK, USA). The cell viability of dermal papilla cells treated with meloside was compared with that of the negative control group (DMEM treatment instead of meloside A or L). The results are shown in Fig. 10.

[0116] As shown in Figure 10, HDPC treated with meloside A showed a cytoprotective effect against DKK1. On the other hand, HDPC treated with meloside L showed no cytoprotective effect against DKK1.

[0117]

[0118] [Experimental Example 8] Confirmation of the effect of meloxide treatment on hair loss and inflammation relief.

[0119] We confirmed the anti-inflammatory effects of meloside A and L.

[0120] Specifically, (i) a negative control group in which HDPCs, which are hair papilla cells, were not treated with either dihydrotestosterone (DHT) or meloside A and L; (ii) an untreated group in which HDPCs were treated with 100 ug / mL DHT and neither meloside A nor L; (iii) a positive control group in which HDPCs were treated with 100 μM minoxidil or 20 μM dexamethasone (DEX); and (iv) a treatment group in which HDPCs were treated with 100 ug / mL DHT to increase the expression level of IL-6 and then treated with meloside A or L at a concentration of 30 or 100 ppm for 1 day, respectively; and then the cell supernatants of HDPCs in (i) to (iv) were obtained and the increase or decrease in the expression level of IL-6 (Interleukin 6) was confirmed through enzyme-linked immunosorbent assay (ELISA). Here, for the analysis of the expression pattern for each sample, correction was made based on the standard sample of IL-6, and the results are shown in Figure 11.

[0121] As shown in Figure 11, the decrease in IL-6 expression in HDPC treated with meloside A reduced DHT-induced inflammation, confirming the effect of alleviating scalp inflammation by reducing IL-6 expression. On the other hand, it was confirmed that there was no effect of reducing IL-6 expression in HDPC treated with meloside L.

[0122]

[0123] [Experimental Example 9] Confirmation of the inhibitory effect of meloside treatment on reactive oxygen species (ROS) induced by dihydrotestosterone (DHT).

[0124] The inhibitory effect on intracellular reactive oxygen species was evaluated using human dermal papilla cells (HDPC), and was measured using the principle that the non-fluorescent substance 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA) reacts with free radicals generated within the cells and is oxidized to the fluorescent substance 2',7'-dichlorofluorescein (DCF).

[0125] Human breast papilla cells were seeded at 5.5 x 10 in 12-well plates. 4 After dividing into 10 cells / well and culturing for 24 hours in a 37℃, 5% CO2 incubator, each well was treated with samples prepared at different concentrations and cultured for 23 hours in a 37℃, 5% CO2 incubator. The treatment group was treated with 30 or 100 ppm of meloside A or L together with DHT, respectively. As a control group, a group treated with 100 ug / mL DHT without treatment with meloside A or L and an untreated group without treatment with meloside A or L and without DHT were used in the experiment. In addition, a positive control group was used in which 5 mM NAC or 10 μM minoxidil was treated instead of meloside A or L. After culturing the wells with 100 ug / mL DHT or meloside in an incubator for 24 hours, 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA, fluorescent probe) was added and reacted at room temperature for 30 minutes. DCF-DA was removed, washed twice with PBS, and images were taken at Ex 485 nm and Em 535 nm using a fluorescence microscope at 10-minute intervals for 30 minutes. The degree of intracellular reactive oxygen species production was measured by measuring the fluorescence intensity of 100 cells using Image J, and the reactive oxygen species (ROS) reduction effect of meloside was confirmed through this, and the results are shown in Figs. 12 and 13.

[0126] As shown in Figures 12 and 13, it was confirmed that the treatment of HDPC with meloside A and L had an effect of improving hair loss (preventing hair loss, etc.) by suppressing ROS, a factor that causes hair loss induced by DHT, through a decrease in the production of reactive oxygen species (ROS).

[0127]

[0128] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A composition for alleviating hair loss and improving hair growth, comprising meloside, an isomer thereof, a hydrate thereof, a solvate thereof, or a salt thereof represented by the following chemical formula 1 as an effective ingredient: [Chemical Formula 1] .

2. In the first paragraph, the composition is characterized in that the meloside is at least one selected from the group consisting of meloside A represented by the following chemical formula 2 and meloside L represented by the following chemical formula 3: [Chemical formula 2] [Chemical Formula 3] .

3. A composition according to claim 1 or 2, characterized in that the composition is for preventing or improving male pattern baldness.

4. A composition according to claim 1 or 2, characterized in that the composition increases the growth of mammary gland cells.

5. A composition according to claim 1 or 2, characterized in that the composition reduces the expression of androgen receptor.

6. A composition according to claim 1 or 2, characterized in that the composition prevents death of mammary papilla cells.

7. A composition according to claim 1 or 2, characterized in that the composition alleviates scalp inflammation.

8. A composition according to claim 1 or 2, characterized in that the composition reduces the production of active oxygen, which is a hair loss-causing factor.

9. A composition according to claim 1 or 2, characterized in that the composition is a cosmetic composition, a health functional food composition, or a pharmaceutical composition.

10. Use of meloside, its isomer, its hydrate, its solvate or its salt represented by chemical formula 1 as an effective ingredient in the manufacture of a composition for alleviating hair loss and improving hair growth: [Chemical Formula 1] .

11. In the 10th paragraph, the use is characterized in that the meloside is at least one selected from the group consisting of meloside A represented by the following chemical formula 2 and meloside L represented by the following chemical formula 3: [Chemical formula 2] [Chemical Formula 3] .

Images